Northern Trust Corp Has $20.24 Million Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Northern Trust Corp boosted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 892,425 shares of the life sciences company's stock after purchasing an additional 80,090 shares during the quarter. Northern Trust Corp owned about 1.16% of Integra LifeSciences worth $20,240,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Capital Research Global Investors grew its stake in Integra LifeSciences by 7.4% in the fourth quarter. Capital Research Global Investors now owns 1,400,559 shares of the life sciences company's stock valued at $31,765,000 after acquiring an additional 95,944 shares during the period. Lord Abbett & CO. LLC grew its stake in Integra LifeSciences by 86.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock valued at $30,210,000 after acquiring an additional 618,773 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Integra LifeSciences by 10.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company's stock valued at $23,759,000 after acquiring an additional 103,291 shares during the period. Principal Financial Group Inc. grew its stake in Integra LifeSciences by 5.5% in the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock valued at $9,603,000 after acquiring an additional 22,000 shares during the period. Finally, Leeward Investments LLC MA grew its stake in Integra LifeSciences by 7.8% in the fourth quarter. Leeward Investments LLC MA now owns 405,506 shares of the life sciences company's stock valued at $9,197,000 after acquiring an additional 29,402 shares during the period. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Stock Down 0.1%

NASDAQ IART traded down $0.02 during trading hours on Monday, hitting $13.55. 1,061,813 shares of the company traded hands, compared to its average volume of 1,048,128. The business's 50-day moving average is $17.82 and its 200-day moving average is $21.66. Integra LifeSciences Holdings Co. has a twelve month low of $11.60 and a twelve month high of $32.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -150.54, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. During the same period last year, the company posted $0.55 earnings per share. The business's revenue for the quarter was up 3.7% on a year-over-year basis. Sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on IART. Wells Fargo & Company decreased their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. JMP Securities decreased their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Truist Financial reduced their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Finally, JPMorgan Chase & Co. reduced their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $18.63.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.